NasdaqGS - Nasdaq Real Time Price USD

PepGen Inc. (PEPG)

1.5800

+0.0900

+(6.04%)

At close: 4:00:00 PM EDT

1.5800

0.00

(0.00%)

After hours: 4:05:17 PM EDT

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

BOSTON, May 20, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as wel

Business Wire 10 hours ago

PEPG
+6.04%
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

BOSTON, May 08, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025.

Business Wire 12 days ago

PEPG
+6.04%
Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. last month

PEPG
+6.04%
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

BOSTON, April 02, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 1:30pm ET.

Business Wire last month

PEPG
+6.04%
PepGen Announces Appointment of Two New Directors to its Board

BOSTON, March 31, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company.

Business Wire last month

PEPG
+6.04%
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

BOSTON, March 10, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting two oral presentations as well as five posters at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 16-19, 2025 in Dallas, TX. The oral presentations featur

Business Wire 2 months ago

PEPG
+6.04%
PepGen pauses Phase II DMD trial to review safety data

PepGen has previously faced an FDA clinical hold on the investigational new drug application of PGN-ENO51 in the Phase II CONNECT2 trial.

Clinical Trials Arena 2 months ago

PEPG
+6.04%

GLDAF
PepGen to Participate in Upcoming Investor Conferences

BOSTON, March 04, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:

Business Wire 2 months ago

PEPG
+6.04%
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

BOSTON, March 04, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the Company can review results from the 10 mg/kg cohort in the ongoing Phase 2 CONNECT1-EDO5

Business Wire 2 months ago

PEPG
+6.04%
PepGen reports positive initial data from Phase I DM1 therapy trial

The therapy has shown a 'favourable' emerging safety profile in both the 5mg/kg and 10mg/kg cohorts.

Clinical Trials Arena 2 months ago

PEPG
+6.04%
PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

BOSTON, February 24, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2024, and recent corporate highlights.

Business Wire 2 months ago

PEPG
+6.04%
PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

BOSTON, February 24, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1).

Business Wire 2 months ago

PEPG
+6.04%
PepGen price target lowered to $16 from $26 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on PepGen (PEPG) to $16 from $26 and keeps a Buy rating on the shares after the company shared the safety reports from the CONNECT1-EDO51, the Phase 2, open-label, multiple ascending dose clinical trial being conducted in Canada. The important takeaway is that the two patients who were reported to have asymptomatic hypomagnesemia have returned to the normal baseline level with the help of oral magnesium supplementation suggesting the effect is reve

TipRanks 3 months ago

PEPG
+6.04%
PepGen Announces CONNECT Program Updates

BOSTON, January 29, 2025--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) for patients amenable to an exon-51 skipping approach.

Business Wire 3 months ago

PEPG
+6.04%
All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy

PepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 4 months ago

PEPG
+6.04%
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

BOSTON, December 16, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company received a clinical hold notice from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application to initiate the CONNECT2-EDO51 clinical trial in patients with Duchenne muscular

Business Wire 5 months ago

PEPG
+6.04%
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

BOSTON, November 21, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its newly appointed Senior Vice President, Clinical Development, Steve Han, MD, PhD, MMSc.

Business Wire 5 months ago

PEPG
+6.04%
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

BOSTON, November 07, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2024.

Business Wire 6 months ago

PEPG
+6.04%
We're Keeping An Eye On PepGen's (NASDAQ:PEPG) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 6 months ago

PEPG
+6.04%
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society

BOSTON, October 08, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting a short oral presentation as well as five posters at the 29th Annual Congress of the World Muscle Society (WMS), being held October 8-12, 2024 in Prague, Czech Republic.

Business Wire 7 months ago

PEPG
+6.04%

Performance Overview

Return	PEPG	S&P 500 (^GSPC)
YTD	-58.31%	+1.00%
1-Year	-88.29%	+11.91%
3-Year	-85.94%	+52.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PepGen Inc. (PEPG)

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

PepGen Announces Appointment of Two New Directors to its Board

PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

PepGen pauses Phase II DMD trial to review safety data

PepGen to Participate in Upcoming Investor Conferences

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

PepGen reports positive initial data from Phase I DM1 therapy trial

PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

PepGen price target lowered to $16 from $26 at H.C. Wainwright

PepGen Announces CONNECT Program Updates

All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

We're Keeping An Eye On PepGen's (NASDAQ:PEPG) Cash Burn Rate

PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society

Performance Overview